Related Experiment Video
Updated: Aug 9, 2026
10:27
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
Published on: December 15, 2011
A Case Report of a Patient With Recalcitrant Pemphigus Vulgaris Treated With Rituximab
Mahlatse Cordelia Kgokolo1, Lesedi Makgwethele Nevondo2, Michaela Beetge3
1Department of Dermatology, School of Medicine, Faculty of Health Sciences University of Pretoria Pretoria South Africa.
Clinical Case Reports
|August 2, 2026
Summary
Pemphigus vulgaris treatment varies by location. Skin lesions improved with corticosteroids, but severe mouth sores needed rituximab for remission, showing personalized therapy is key.
Area of Science:
- Dermatology
- Immunology
Background:
- Pemphigus vulgaris is an autoimmune blistering disease.
- It can affect skin and mucous membranes.
Purpose of the Study:
- To report a case of pemphigus vulgaris with differential treatment responses.
- To emphasize the need for tailored therapeutic strategies.
Main Methods:
- Case report.
- Treatment with high-dose corticosteroids for cutaneous lesions.
- Treatment with rituximab for oral lesions.
Main Results:
- Cutaneous lesions showed positive response to high-dose corticosteroids.
- Refractory oral lesions achieved remission with rituximab.
- Sustained disease control was obtained through multimodal therapy.
Conclusions:
- Pemphigus vulgaris requires individualized treatment approaches.
- Multimodal therapy is essential for managing refractory cases.
- Differential responses necessitate adaptive treatment strategies.
